MedTrace Logo

Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer

NCT00003183 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2013-12-04

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with G-CSF may make tumor cells more sensitive to the chemotherapy drug and may kill more tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of mitoxantrone plus G-CSF in treating patients with metastatic prostate cancer that has not responded to hormone therapy.

Conditions

Interventions

BIOLOGICAL

filgrastim

DRUG

mitoxantrone hydrochloride

Sponsors & Collaborators

  • Hope Cancer Institute, Inc.

    lead INDUSTRY

Principal Investigators

  • Raj Sadasivan, MD, PhD · Hope Cancer Institute, Inc.

Study Design

Purpose
TREATMENT

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003183 on ClinicalTrials.gov